Core Viewpoint - The stock market experienced a collective rise on June 9, with the Shanghai Composite Index up by 0.43%, the Shenzhen Component Index up by 0.65%, and the ChiNext Index up by 1.07%, indicating a positive market sentiment with over 4,100 stocks rising [1]. Sector Performance - The pharmaceutical sector saw significant gains, particularly in the CRO (Contract Research Organization) and innovative drug segments, leading the market [4]. - The CRO concept rose by 4.73%, with a net inflow of 1.59 billion and a main capital inflow of 8.09 million [5]. - The innovative drug sector also performed well, with a 3.91% increase, and notable stocks like Xinghao Pharmaceutical rising over 27% [5][6]. - The rare earth permanent magnet sector also showed strong performance, with stocks like Keheng Co. and Jiuling Technology experiencing gains of 20% and 18%, respectively [6]. Capital Flow - Main capital saw a net inflow into sectors such as pharmaceuticals, electronics, power equipment, and media, while there was a net outflow from banking, liquor, and transportation sectors [8]. - Specific stocks like Jianghuai Automobile, Cross-Border Communication, and Dongfang Wealth received net inflows of 970 million, 846 million, and 690 million, respectively [8]. Institutional Insights - Guoyuan Securities noted that the market may face short-term pressure at integer points, with potential fluctuations before stabilizing [10]. - Dongfang Securities observed a recovery in institutional positions, indicating a continued upward trend in pharmaceutical sector valuations [11]. - Caitong Securities suggested that the market is in a phase of policy support and external balancing, predicting a range-bound index between 3,330 and 3,450 points, with a focus on technology, consumption, and defensive sectors for balanced portfolio management [11].